Embracing a One Health Framework to Fight Antimicrobial Resistance



Antimicrobial resistance (AMR) – the ability of microbes to resist antimicrobials - remains an alarming global health threat that jeopardises the effectiveness of many 20th century public health advances. The latest OECD analysis shows that across 34 OECD and EU/EEA countries, AMR is estimated to claim more than 79 thousand lives every year, with the annual costs to health systems nearing USD PPP 29 billion. Adopting a multisectoral approach called the One Health framework is vital to tackling the complex drivers of AMR across human health, animal health, agrifood systems and the environment.

In recent years, France made important strides in tackling AMR. Yet, more progress is needed:



Resistance proportions for 12 antibiotic-bacterium pairs increased slightly between 2005 and 2019 (11.8% vs 13.8%) but averaged below the EU/EEA average (21.3% in 2019). If left unchecked, resistance proportions are projected to decline slightly to 12.9% by 2035, averaging below the expected EU/EEA average (20.3%).



Without further policy action, resistance proportions for penicillin-resistant *Streptococcus pneumoniae and* fluoroquinolone resistant *Escherichia coli* are expected to grow at the fastest pace between 2019 and 2035 (4.7 and 3.5 percentage points respectively). Growing resistance in these antibiotic-bacterium pairs can undermine the treatment of illnesses such as pneumonia, bloodstream infections, diarrhea and urinary tract infections.




Total antibiotic consumption in human health averaged at 35.7 defined daily dose (DDD) per 1 000 persons per day in 2015, above the EU/EEA average (24.2). If trends persist, total antibiotic consumption is expected to decline slightly to 34.8 DDD per 1 000 persons by per day by 2030, remaining above the projected EU/EEA average (23.6).




Access antibiotics – first- and second-line therapies with lower resistance potential – made up nearly 68% of all antibiotics consumed in France in 2015, exceeding the WHO target for Access antibiotics to make up at least 60% of national consumption.

AMR continues to pose a worrisome threat to population health and healthcare budget in France:



Note: The impact of AMR on population health is modelled by the OECD using two scenarios: 1) Elimination Scenario and 2) Replacement Scenario. The Elimination Scenario assumes elimination of all the resistant infections whereas the Replacement Scenario considers a situation where all resistant infections are assumed to be completely replaced by susceptible infections. Both scenarios are seen as plausible due to the dearth of concluding evidence in the literature.

France performs well in most policy areas but there is room for further policy action:



The following priorities for action are identified to align policies with the *Global Action Plan* to Tackle AMR:

- Optimising antimicrobial use in human health to ensure national guidelines are implemented and data on antimicrobial use is systematically fed back to prescribers.
- Improving the national monitoring system for consumption and rational use of antimicrobials in human health to ensure regular data collection on a) antimicrobial sales/or consumption and b) prescribing and rational use in a representative sample of healthcare facilities.
- Enhancing monitoring and evaluation arrangements to ensure adoption of and compliance with antimicrobial stewardship and IPC programmes in long-term care facilities.

Notes: 1- least developed; 5 – most developed; diamonds indicate mode for OECD and EU/EEA countries; country scores are denoted in light blue. Source: 2021-22 Tripartite AMR Self-Assessment Survey

The One Health approach underscores the importance of pairing policies across sectors. The OECD examined the impact of different policies including a mixed policy package that would involve the scaling-up of 5 policy priorities across sectors.



Improve antibiotic stewardship



Improve hand hygiene practices in healthcare settings



Delayed antimicrobial prescription





Increase mass media campaigns



Enhance food safety

In France, investing 4 EURs per person annually in a mixed policy package can yield important gains every year:

68 883

Infections prevented

886

Lives saved

Savings in healthcare costs (in million EURs)

212

Gains by increased workforce participation and productivity (in million EURs)

173

Return per EUR invested

1.39



